0 Gamma Knife Centre, Cromwell Hospital and the London Gamma Knife Centre/St. Bartholomew's and the Royal London Hospital, London, United Kingdom; and Department of Neurosurgery, Karolinska Hospital, Stockholm, Sweden
✓A dose gradient index (GI) is proposed that can be used to compare treatment plans of equal conformity. The steep dose gradient outside the radiosurgical target is one of the factors that makes radiosurgery possible. It therefore makes sense to measure this variable and to use it to compare rival plans, explore optimal prescription isodoses, or compare treatment modalities.
The GI is defined as the ratio of the volume of half the prescription isodose to the volume of the prescription isodose. For a plan normalized to the 50% isodose line, it is the ratio of the 25% isodose volume to that of the 50% isodose volume.
The GI will differentiate between plans of similar conformity, but with different dose gradients, for example, where isocenters have been inappropriately centered on the edge of the target volume.
In a retrospective series of 50 dose plans for the treatment of vestibular schwannoma, the optimal prescription isodose was assessed. A mean value of 40% (median 38%, range 30–61%) was calculated, not 50% as might be anticipated. The GI can show which of these prescription isodoses will give the steepest dose falloff outside the target.
When planning a multiisocenter treatment, there may be a temptation to place some isocenters on the edge of the target. This has the apparent advantage of producing a plan of good conformity and a predictable prescription isodose; however, it risks creating a plan that has a low dose gradient outside the target. The quality of this dose gradient is quantified by the GI.
Abbreviations used in this paper: GI = gradient index; GKS = Gamma Knife surgery; PIV = prescription isodose volume.
AndrewsDSuarezOGoldmanHDownesMBednarzGCornB: Stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of acoustic schwannomas: comparative observations of 125 patients treated at one institution.Int J Radiat Oncol Biol Phys50:1265–12782001
FlickingerJCKondziolkaDLunsfordLDKassamAPhuongLKLiščákR: Development of a model to predict permanent symptomatic postradiosurgery injury for arteriovenous malformation patients.Int J Radiat Oncol Biol Phys46:1143–11482000
MassagerNNissimODelbrouckCDevriendtDDavidPDesmedtF: Role of intracanalicular volumetric and dosimetric parameters on hearing preservation after vestibular schwannoma radiosurgery.Int J Radiat Oncol Biol Phys64:1331–13402006
RoweJGRadatzMWRWaltonLSoanesTRodgersJKemenyAA: Clinical experience with Gamma Knife radiosurgery in the management of vestibular schwannoma secondary to type 2 neurofibromatosis.J Neurol Neurosurg Psychiatry74:1288–12932003
SampathPRiniDLongD: Microanatomical variations in the cerebellopontine angle associated with vestibular schwannomas (acoustic neuromas): a retrospective study of 1006 consecutive cases.J Neurosurg92:70–782000
ShawEScottCSouhamiLDinapoliRKlineRLoefflerJ: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of the RTOG protocol 90-05.Int J Radiat Oncol Biol Phys47:291–2982000
SneedPKSuhJHGoetschSJSanghaviSNChappellRBuattiJM: A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases.Int J Radiat Oncol Biol Phys53:519–5262002
VarlottoJMFlickingerJCNiranjanABhatnagarAKKondziolkaDLunsfordLD: Analysis of tumor control and toxicity in patients who have survived at least one year after radiosurgery for brain metastases.Int J Radiat Oncol Biol Phys57:452–4642003
WowraBMuacevicAJess-HempenAHempelJMMüller-SchunkSTonnJC: Outpatient Gamma Knife surgery for vestibular schwannoma: definition of the therapeutic profile based on a 10-year experience.J Neurosurg (Suppl)102:114–1182005